Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review

Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review

AimSince 2021, additional real-world evidence (RWE) has emerged on the effectiveness of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as first-line treatment of HR-positive/HER2-negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC), necessitating this updated review.MethodsMEDLINE®, Emba...

Full description

Saved in:
Bibliographic Details
Main Authors: Nadia Harbeck, Adam Brufsky, Chloe Grace Rose, Beata Korytowsky, Connie Chen, Krista Tantakoun, Endri Jazexhi, Do Hoang Vien Nguyen, Meaghan Bartlett, Imtiaz A. Samjoo, Timothy Pluard
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Oncology
Subjects:
CDK4/6 inhibitors
quality assessment
breast
metastasis
real-world evidence
systematic literature review
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1530391/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items